Merck & Co. isn’t resting on Keytruda’s laurels. But an attempt to improve on the undoubtful cancer immunotherapy king with another agent has failed in …
Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …
Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be …
Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
